Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 14/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | MMP3 | P08254 | 1/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.54 |
| ▸ | MMP8 | P22894 | 1/20 | 0.54 |
| ▸ | MMP12 | P39900 | 1/20 | 0.54 |
| ▸ | MMP13 | P45452 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | UBE2N | P61088 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14261926 | 0.91 | CTSA (0.64) | CTSA | |
| SCHEMBL14261994 | 0.87 | CTSA (0.50) | CTSAEPHX2MMP3MMP9MMP8 | |
| SCHEMBL6188521 | 0.86 | TACR3 (0.53) | CTSAEPHX2KDM4ELMNAOPRK1 | |
| SCHEMBL9848406 | 0.85 | AKT1 (0.61) | EPHX2KDM4ELMNAOPRK1HTT | |
| SCHEMBL14261995 | 0.82 | CTSA (0.52) | CTSAEPHX2KDM4ESMN1; SMN2 | |
| SCHEMBL14261920 | 0.81 | NPC1 (0.58) | CTSALMNAHTTSMN1; SMN2 | |
| SCHEMBL14261925 | 0.81 | NPC1 (0.58) | CTSAKDM4ESMN1; SMN2 | |
| SCHEMBL27883399 | 0.81 | EPHX2 (0.50) | CTSAEPHX2KDM4ELMNAOPRK1 | |
| SCHEMBL14261998 | 0.80 | CTSA (0.50) | CTSA | |
| SCHEMBL28928009 | 0.80 | HTT (0.60) | EPHX2KDM4ELMNAOPRK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348357-B2 | bactericide; derivatives of pseudopeptide Andrimid in which beta-phenylalanine amide is replaced by heteroaromatic or substituted aromatic amide; N-{(1S)-3-[((1S)-1-{[(3R,4S)-1,4-Dimethyl-2,5-dioxo-3-pyrrolidinyl]carbonyl}-2-methylpropyl)amino]-3-oxo-1-phenylpropyl}-2-pyridinecarboxamide; antibiotics | BAYER HEALTHCARE AG (DE) | 2008-03-25 | — | — | US | disclosed |
| US-7348357-B2 | bactericide; derivatives of pseudopeptide Andrimid in which beta-phenylalanine amide is replaced by heteroaromatic or substituted aromatic amide; N-{(1S)-3-[((1S)-1-{[(3R,4S)-1,4-Dimethyl-2,5-dioxo-3-pyrrolidinyl]carbonyl}-2-methylpropyl)amino]-3-oxo-1-phenylpropyl}-2-pyridinecarboxamide; antibiotics | BAYER HEALTHCARE AG (DE) | 2008-03-25 | — | — | US | disclosed |
| US-7348357-B2 | bactericide; derivatives of pseudopeptide Andrimid in which beta-phenylalanine amide is replaced by heteroaromatic or substituted aromatic amide; N-{(1S)-3-[((1S)-1-{[(3R,4S)-1,4-Dimethyl-2,5-dioxo-3-pyrrolidinyl]carbonyl}-2-methylpropyl)amino]-3-oxo-1-phenylpropyl}-2-pyridinecarboxamide; antibiotics | BAYER HEALTHCARE AG (DE) | 2008-03-25 | — | — | US | disclosed |
| US-20060173040-A1 | Arylamides | BAYER HEALTHCARE AG (DE) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173040-A1 | Arylamides | AADAC, AHR, ARSA | CTSA 91/4885EPHX2 1405/4885MMP3 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.